KORU Medical Systems Announces CEO Retirement and Succession Plan, Appointing Adam Kalbermatten as New CEO
Summary
KORU Medical Systems announced the planned retirement of CEO Linda Tharby effective June 30, 2026, and the appointment of Adam Kalbermatten as President, who will become CEO on July 1, 2026, ensuring an orderly leadership transition.
Key Events
-
CEO Retirement Announced
Linda Tharby will retire as President and Chief Executive Officer effective June 30, 2026. She will continue to serve as a non-executive advisory employee and Board member through December 31, 2026, to facilitate an orderly transition.
-
New CEO Appointed
Adam Kalbermatten has been appointed President effective March 15, 2026, and will succeed Ms. Tharby as Chief Executive Officer effective July 1, 2026. He is also slated to join the Board of Directors on January 1, 2027.
-
Performance-Aligned Compensation for New CEO
Mr. Kalbermatten's compensation includes a one-time $1,250,000 promotion grant of Performance Share Units (PSUs) effective July 1, 2026, with vesting tied to multi-year revenue growth (75%) and market capitalization (25%) objectives. His 2026 target long-term incentive (LTI) award is also $1,250,000.
-
Orderly Transition Plan
The company has established a structured transition plan, including an advisory period for the outgoing CEO and specific equity vesting terms, to ensure leadership continuity and stability.
Analysis
This 8-K details a significant leadership transition at KORU Medical Systems, with the planned retirement of CEO Linda Tharby and the appointment of Adam Kalbermatten as her successor. The structured transition, including an advisory period for Ms. Tharby and a clear timeline for Mr. Kalbermatten's assumption of the CEO role, signals stability and continuity. Mr. Kalbermatten's compensation package, particularly the substantial performance-based equity awards tied to revenue growth and market capitalization, aligns his incentives directly with shareholder value creation. This strategic leadership change, occurring shortly after the company reported robust financial results, positions KORU Medical Systems for its next phase of growth.
At the time of this filing, KRMD was trading at $4.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $198.5M. The 52-week trading range was $1.86 to $6.61. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.